Literature DB >> 29097554

Restless Legs Syndrome: clinical features, diagnosis and a practical approach to management.

Subhashie Wijemanne1, William Ondo2.   

Abstract

Restless legs syndrome (RLS) is a chronic neurological disorder that interferes with rest and sleep. It has a wide spectrum of symptom severity, and treatment is started when symptoms become bothersome. Dopamine agonists and calcium channel apha-2-delta antagonists (gabapentin, gabapentin enacarbil and pregabalin) are first-line treatments; calcium channel alpha-2-deltas are preferred over dopamine agonists because they give less augmentation, a condition with symptom onset earlier in the day and intensification of RLS symptoms. Dopamine agonists can still be used as first-line therapy, but the dose should be kept as low as possible. Iron supplements are started when the serum ferritin concentration is ≤75 µg/L, or if the transferrin saturation is less than 20%. For severe or resistant RLS, a combined treatment approach can be effective. Augmentation can be very challenging to treat and lacks evidenced-based guidelines. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  augmentation; dopamine agonist; iron; periodic limb movement disorder; restless legs syndrome

Mesh:

Year:  2017        PMID: 29097554     DOI: 10.1136/practneurol-2017-001762

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  21 in total

1.  Performance of the American College of Rheumatology 2016 criteria for fibromyalgia in a referral care setting.

Authors:  Sakir Ahmed; Amita Aggarwal; Able Lawrence
Journal:  Rheumatol Int       Date:  2019-05-17       Impact factor: 2.631

Review 2.  The Comorbidity of Migraine and Restless Legs Syndrome.

Authors:  Semiha Kurt
Journal:  Curr Neurol Neurosci Rep       Date:  2019-07-27       Impact factor: 5.081

3.  Restless legs syndrome is associated with mast cell activation syndrome.

Authors:  Leonard B Weinstock; Arthur S Walters; Jill B Brook; Zahid Kaleem; Lawrence B Afrin; Gerhard J Molderings
Journal:  J Clin Sleep Med       Date:  2020-01-14       Impact factor: 4.062

4.  Anesthetic Management of a Patient With Restless Legs Syndrome: A Case Report.

Authors:  Naohiro Ohshita; Koji Yamagata; Akio Himejima; Kazuhiro Kaneda; Teruyuki Yasutome; Yoshiko Matsuda; Yasuo M Tsutsumi; Yoshihiro Momota
Journal:  Anesth Prog       Date:  2020-12-01

5.  Challenges in the Treatment of Restless Legs Syndrome: A Case Report.

Authors:  Audrey Umbreit; Shirshendu Sinha; Bhanu Prakash Kolla; Meghna P Mansukhani
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

6.  The efficacy and tolerability of rotigotine on patients with periodic limb movement in sleep: A systematic review and meta-analysis.

Authors:  Meng-Ni Wu; Ping-Tao Tseng; Tien-Yu Chen; Yen-Wen Chen; Li-Min Liou; Pao-Yen Lin; Chung-Yao Hsu
Journal:  PLoS One       Date:  2018-04-18       Impact factor: 3.240

7.  Acupuncture for restless legs syndrome: A systematic review and meta-analysis protocol.

Authors:  Kaiyu Huang; Shuang Liang; Dong Han; Rubao Guo; Lei Chen; Antoine Grellet
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

Review 8.  Restless Legs Syndrome across the Lifespan: Symptoms, Pathophysiology, Management and Daily Life Impact of the Different Patterns of Disease Presentation.

Authors:  Giuseppe Didato; Roberta Di Giacomo; Giuseppa Jolanda Rosa; Ambra Dominese; Marco de Curtis; Paola Lanteri
Journal:  Int J Environ Res Public Health       Date:  2020-05-22       Impact factor: 3.390

9.  Clinical Predictors of Excessive Daytime Sleepiness in Patients with Parkinson's Disease.

Authors:  Bruno Terra Junho; Arthur Kummer; Francisco Cardoso; Antonio Lucio Teixeira; Natalia Pessoa Rocha
Journal:  J Clin Neurol       Date:  2018-09-06       Impact factor: 3.077

10.  Botulinum Toxin in Restless Legs Syndrome-A Randomized Double-Blind Placebo-Controlled Crossover Study.

Authors:  Shivam Om Mittal; Duarte Machado; Diana Richardson; Divyanshu Dubey; Bahman Jabbari
Journal:  Toxins (Basel)       Date:  2018-09-29       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.